The Dexlansoprazole market is poised for steady expansion through 2031 as demand for effective gastroesophageal reflux disease (GERD) therapies continues to rise worldwide. Dexlansoprazole, a proton pump inhibitor (PPI), is widely used for treating GERD and healing erosive esophagitis, making it an essential therapy in modern gastrointestinal treatment protocols. Increasing digestive health...